Cyclica improves drug discovery pipelines by identifying expensive risks such as adverse effects, contraindications, and lack of efficacy using Ligand Express™
iCrowdNewswire -
Oct 12, 2016 12:27 PM ET
Cyclica Inc.
Cyclica improves drug discovery pipelines by identifying expensive risks such as adverse effects, contraindications, and lack of efficacy using Ligand Express™
Company Summary
Cyclica improves drug discovery pipelines by identifying expensive risks such as adverse effects, contraindications, and lack of efficacy. Ligand Express™ is a fast and effective platform that searches all structurally known proteins in the human body for potential drug-protein interactions.
Naheed joined Cyclica in March 2014 as VP, Finance and was appointed as CFO in October 2014. In his role as CFO, he has been integral in not only financial management, fundraising, and investor relations, but also in strategic planning and business development. In April 2016, the Board of Directors appointed Naheed as President and Interim-CEO, where he will continue to uphold his responsibilities as CFO.
Gary Kivenko
Vice President, Operations
Unconfirmed
Gary Kivenko is an experienced management professional with specialties in both operations and marketing strategy. Gary has worked in both large enterprise organizations, as well as emerging businesses. As Cyclica’s Vice President, Operations, he oversees business planning and execution, ensuring that the business is scaled and delivers to clients.
Andreas brings to Cyclica 20 years of experience in computational biology, pharmacogenomics, and bioinformatics. Prior to joining Cyclica, Andreas served as Chief Information Officer at Firefly BioWorks, a biotechnology company started out of MIT, where he created all computational aspects of the company’s multiplexed assay technology.